An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination

Juan Manuel Carreño(Icahn School of Medicine at Mount Sinai), Florian Krammer(Icahn School of Medicine at Mount Sinai), Adolfo Garcı́a-Sastre(Icahn School of Medicine at Mount Sinai), Ponthip Wirachwong(Government of Thailand), Sneh Lata Gupta(Emory University), Vladimir Vigdorovich(Infectious Disease Research Institute), Jens Wrammert(Emory University), Mehul S. Suthar(Emory University), Stefan Slamanig(Icahn School of Medicine at Mount Sinai), José Luis Martínez(Icahn School of Medicine at Mount Sinai), Hisaaki Kawabata(Icahn School of Medicine at Mount Sinai), Charles Gleason(Icahn School of Medicine at Mount Sinai), Punnee Pitisuttithum(Mahidol University), Komal Srivastava(Icahn School of Medicine at Mount Sinai), Ariel Raskin(Icahn School of Medicine at Mount Sinai), Sant Muangnoicharoen(Mahidol Oxford Tropical Medicine Research Unit), Johnstone Tcheou(Icahn School of Medicine at Mount Sinai), Gagandeep Singh(Icahn School of Medicine at Mount Sinai), Rama Raghunandan(Program for Appropriate Technology in Health), D. Noah Sather(University of Washington), Irene González‐Domínguez(Icahn School of Medicine at Mount Sinai), Viviana Simon(Icahn School of Medicine at Mount Sinai), Weina Sun(Icahn School of Medicine at Mount Sinai), Nicholas Dambrauskas(Infectious Disease Research Institute), Peter Palese(Icahn School of Medicine at Mount Sinai)
Science Translational Medicine
February 15, 2023
Cited by 23


Related Papers